SecBot SecBot
SECBOTREPLAY Home › Report › QURE

QURE · uniQure announced that the FDA has accepted for review its Biologics…

uniQure N.V. · 8-K filed Nov 2, 2026 at 07:15 ET

At the news

BULLISHIMPACT 7/10

8-K filed Nov 2, 2026 at 07:15 ET

uniQure announced that the FDA has accepted for review its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, under the Accelerated Approval pathway with Priority Review and a PDUFA target action date of May 1, 2027. The FDA is tentatively planning an Advisory Committee meeting, and the company has aligned with the FDA on a confirmatory study design. This is a significant regulatory milestone for a first-in-class therapy in an area with no approved disease-modifying treatments.

  • FDA accepted BLA for ifezuntirgene inilparvovec for Huntington's disease under Accelerated Approval pathway
  • Priority Review granted with PDUFA target action date of May 1, 2027
  • FDA tentatively planning an Advisory Committee meeting
  • BLA supported by 36-month Phase I/II data vs propensity score-matched external control (Enroll-HD database)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access